IRLAB A
17.95
SEK
TODAY
-4.52 %
TODAY SEK
-0.85 SEK
17:00:00
2024-03-18
YEAR LOW
7.6 SEK
YEAR HIGH
20.2 SEK
ATH:
108.09 SEK
MCAP:
931 MSEK

CEO COMMENTS

Gunnar Olsson comments Q4 report 2023

“We have recently completed the compilation of a Briefing Package on mesdopetam as part of the preparations for the upcoming end-of-Phase 2 meeting with the FDA. The agency has confirmed a meeting with us scheduled for February 20. This is an important milestone towards finalizing the planning of Phase III for mesdopetam. In December, the highly respected The Michael J. Fox Foundation announced that it had decided to finance IRLAB and the company’s work with the substance IRL757 for the treatment of apathy with just over 2 million USD to conduct a clinical Phase I study. Both of these events are remarkable as they both constitute external validation and reinforce the quality of the research and development work that IRLAB conducts. I would also like to take this opportunity to give praise to all employees who have contributed to these acknowledgments from world-leading evaluators of pharmaceutical projects.”

LATEST REPORTS

LATEST PRESS RELEASE
FEBRUARY 29, 2024

IRLAB to present at Life Science-dagen in Gothenburg and have a fireside chat with ABG

Gothenburg, Sweden, February 29, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will present at the event Life Science-dagen in Gothenburg on March 6. The company will also participate in a fireside chat with ABG, to be published on March 6.

Read More >
LATEST PRESENTATION
MARCH 7, 2024

Fireside chat with Viktor Siewertz, CFO, at ABGSC

Viktor Siewertz, CFO, participated in the ABGSC fireside chat, moderated by Alexander Krämer, analyst at ABGSC, The event was recorded on March 5 and published on March 7, 2024.

Read More >

FINANCIAL CALENDAR

NEXT

week 18 (April 29-May 3)

Annual report

FOLLOWING

May 8, 2024

Interim report January-March 2024